Alan Y Chiang Selected Research

blosozumab

9/2015	The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
2/2015	A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
4/2014	Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan Y Chiang Research Topics

Disease

6	Osteoporosis 02/2016 - 02/2014
3	Metabolic Bone Diseases (Osteopenia) 02/2016 - 02/2015
2	Breast Neoplasms (Breast Cancer) 01/2023 - 01/2019
2	Thrombophilia 01/2021 - 01/2017
2	Thrombosis (Thrombus) 01/2021 - 01/2017
2	Inflammation (Inflammations) 01/2017 - 10/2009
1	Nausea 01/2023
1	Diarrhea 01/2023
1	Vomiting 01/2023
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Weight Gain 01/2021
1	Vascular System Injuries 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Disease Progression 01/2020
1	Disseminated Intravascular Coagulation 01/2017
1	Body Weight (Weight, Body) 01/2017
1	Leukopenia 01/2017
1	Bone Resorption 02/2015
1	Injection Site Reaction 02/2015
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 04/2010
1	Temporal Lobe Epilepsy 10/2009
1	Cardiotoxicity 08/2009
1	Heart Failure 09/2008

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2009
3	abemaciclibIBA 01/2023 - 01/2019
3	blosozumabIBA 09/2015 - 04/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2023 - 01/2019
2	Teriparatide (Parathar)FDA Link 09/2014 - 02/2014
1	Triglycerides (Triacylglycerol)IBA 01/2021
1	CholesterolIBA 01/2021
1	Dietary Fats (Dietary Fat)IBA 01/2021
1	Cyclin-Dependent Kinase 4IBA 01/2020
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020
1	PlatinumIBA 01/2020
1	Dacarbazine (DIC)FDA LinkGeneric 01/2017
1	EndotoxinsIBA 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Hemostatics (Antihemorrhagics)IBA 01/2017
1	CalciumIBA 02/2016
1	LY 353381 (LY353381)IBA 02/2016
1	Vitamin D FDA LinkGeneric 02/2016
1	Monoclonal AntibodiesIBA 02/2015
1	Alendronate (Alendronate Sodium)FDA LinkGeneric 02/2014
1	Natriuretic PeptidesIBA 04/2010
1	PPAR alphaIBA 04/2010
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 04/2010
1	Kainic Acid (Kainate)IBA 10/2009
1	CalpainIBA 10/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2009
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 10/2009
1	Cytochromes c (Cytochrome c)IBA 10/2009
1	Phosphotransferases (Kinase)IBA 08/2009
1	Adrenergic Agents (Adrenergic Drugs)IBA 09/2008

Therapy/Procedure

6	Therapeutics 01/2020 - 02/2014
1	Intraperitoneal Injections 01/2017